Loading
NASDAQHealthcareBiotechnology
Latest quote
$59.75
−$0.65 · -1.08%
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Previous close
$59.75
−$0.65 · -1.08%
Pre-market
$60.10
+$0.35 · +0.59%
Sep 8, 4:50 AM ET
Regular session · ET · Market data may be delayed.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Day range
Current $59.75
52-week range
Current $59.75
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
39
Expensive
Sentiment
63
Bullish
Risk
30
Moderate Risk
Momentum
78
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Day range
Current $59.75
52-week range
Current $59.75
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM151.8M0.19%80.51B USD0.19%$296.01+0.28%
iShares Russell 2000 Growth ETFIWO55.11M0.38%14.7B USD0.24%$377.54+0.12%
iShares Biotechnology ETFIBB41.35M0.38%10.73B USD0.44%$211.92-0.88%
Vanguard Russell 2000 ETFVTWO34.52M0.19%17.4B USD0.06%$119.62+0.25%
T. Rowe Capital Appreciation Equity ETFTCAF33.16M0.38%8.78B USD0.31%$42.83-0.40%
State Street SPDR Portfolio Developed World ex-US ETFSPDW9.15M0.02%42.37B USD0.03%$52.31+0.40%
Fidelity Enhanced Small Cap ETFFESM8.67M0.13%6.49B USD0.28%$47.36+0.21%
ALPS Medical Breakthroughs ETFSBIO7.96M3.20%248.37M USD0.50%$67.66+0.52%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOT. Rowe Capital Appreciation Equity ETFTCAFState Street SPDR Portfolio Developed World ex-US ETFSPDWFidelity Enhanced Small Cap ETFFESMALPS Medical Breakthroughs ETFSBIOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
